Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Investigate the Combination of LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory T-ALL/LBL

NCT06207123 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT06207123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06207123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Investigate the Combination of LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory T-ALL/LBL
Lead sponsor
University of Chicago
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 13, 2024
Completion date
December 1, 2026
Enrollment
15 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, lymphoblastic leukemia, lymphoblastic lymphoma